Symbols / MNOV
MNOV Chart
About
MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. The company develops MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent in Phase 2b/3 clinical trial for treating neurological and other disorders, such as progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction, as well as prevention of acute respiratory distress syndrome, and long COVID. It is also developing MN-001 (tipelukast), an orally bioavailable small molecule compound in Phase 2 clinical trial to treat fibrotic and other metabolic disorders, including nonalcoholic fatty liver disease and hypertriglycedemia. The company has a license agreement with Kyorin Pharmaceuticals for the development and commercialization of MN-166 and MN-001. MediciNova, Inc. was incorporated in 2000 and is headquartered in La Jolla, California.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 66.64M |
| Enterprise Value | 42.74M | Income | -12.00M | Sales | 409.66K |
| Book/sh | 0.84 | Cash/sh | 0.63 | Dividend Yield | — |
| Payout | 0.00% | Employees | — | IPO | — |
| P/E | — | Forward P/E | -3.39 | PEG | — |
| P/S | 162.68 | P/B | 1.60 | P/C | — |
| EV/EBITDA | -3.22 | EV/Sales | 104.34 | Quick Ratio | 8.11 |
| Current Ratio | 8.16 | Debt/Eq | 0.51 | LT Debt/Eq | — |
| EPS (ttm) | -0.25 | EPS next Y | -0.40 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2026-05-13 | ROA | -16.36% |
| ROE | -25.50% | ROIC | — | Gross Margin | 7.58% |
| Oper. Margin | -20.38% | Profit Margin | 0.00% | Shs Outstand | 49.15M |
| Shs Float | 42.26M | Short Float | 0.53% | Short Ratio | 2.42 |
| Short Interest | — | 52W High | 1.96 | 52W Low | 1.13 |
| Beta | 0.55 | Avg Volume | 84.57K | Volume | 115.27K |
| Target Price | $10.00 | Recom | None | Prev Close | $1.49 |
| Price | $1.36 | Change | -8.99% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$10.00
Mean price target
2. Current target
$1.35
Latest analyst target
3. DCF / Fair value
$-2.23
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$1.35
Low
$9.00
High
$11.00
Mean
$10.00
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-01-30 | main | D. Boral Capital | Buy → Buy | $9 |
| 2025-12-18 | main | D. Boral Capital | Buy → Buy | $9 |
| 2025-12-08 | main | D. Boral Capital | Buy → Buy | $9 |
| 2025-11-04 | main | D. Boral Capital | Buy → Buy | $9 |
| 2025-10-31 | main | D. Boral Capital | Buy → Buy | $9 |
| 2025-09-22 | main | D. Boral Capital | Buy → Buy | $9 |
| 2025-08-27 | main | D. Boral Capital | Buy → Buy | $9 |
| 2025-07-24 | main | D. Boral Capital | Buy → Buy | $9 |
| 2025-06-16 | main | B. Riley Securities | Buy → Buy | $5 |
| 2025-04-09 | main | D. Boral Capital | Buy → Buy | $9 |
| 2025-03-14 | main | D. Boral Capital | Buy → Buy | $9 |
| 2025-02-21 | main | D. Boral Capital | Buy → Buy | $9 |
| 2024-12-06 | main | D. Boral Capital | Buy → Buy | $9 |
| 2024-12-02 | init | D. Boral Capital | — → Buy | $9 |
| 2021-03-10 | init | Maxim Group | — → Buy | $15 |
| 2020-03-13 | main | B. Riley Securities | — → Buy | $11 |
| 2018-03-28 | init | B. Riley Securities | — → Buy | $22 |
| 2012-05-24 | main | Ladenburg Thalmann | — → Buy | $11 |
- ALS patients gain wider access as MediciNova trial reaches 100 enrollees - Stock Titan hu, 29 Jan 2026 08
- MediciNova (MNOV) Price Target Increased by 28.57% to 9.18 - Nasdaq Wed, 04 Feb 2026 08
- New Analyst Forecast: $MNOV Given $9 Price Target - Quiver Quantitative Fri, 30 Jan 2026 08
- Why Did MediciNova Stock (MNOV) Jump Over 87% In After-Hours Trading? - Benzinga hu, 30 Oct 2025 07
- MediciNova Stock Rockets 85% After-Hours On Promising Heart Study — Traders Hope For ‘Big Green Candle’ - Stocktwits Fri, 31 Oct 2025 03
- 3 Penny Stocks With Market Caps Over $80M To Consider - simplywall.st Mon, 03 Nov 2025 08
- MediciNova (NASDAQ: MNOV) fully enrolls 234-patient Phase 2b/3 ALS ALS trial, targets 2026 top-line data - Stock Titan Mon, 08 Dec 2025 08
- New Analyst Forecast: $MNOV Given $9.0 Price Target - Nasdaq hu, 24 Jul 2025 07
- What is the next catalyst for Duolingo Inc - Market Volume Report & High Return Trade Opportunity Guides - baoquankhu1.vn Mon, 23 Feb 2026 01
- MediciNova, Inc. Wins Contract Research and Development Innovation Award at BioTech Breakthrough Awards - Quiver Quantitative hu, 06 Nov 2025 08
- MNOV Stock Price, News & Analysis - Stock Titan hu, 24 Apr 2025 23
- Why MediciNova Stock Skyrocketed Today - The Motley Fool Wed, 10 Mar 2021 08
- 13 Best Biotech Penny Stocks To Buy Now - Yahoo Finance ue, 29 Nov 2022 08
- Why Did Strategy Stock Spike Nearly 6% After-Hours? - Stocktwits Fri, 31 Oct 2025 04
- MediciNova Provides Update on COMBAT-ALS Study of MN-166 for Amyotrophic Lateral Sclerosis - Quiver Quantitative Mon, 08 Dec 2025 08
Insider Transactions
No recent insider transactions.
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -12.65M | -9.88M | -14.61M | -10.19M |
| NetIncomeFromContinuingOperationNetMinorityInterest | -11.05M | -8.57M | -14.07M | -10.13M |
| ReconciledDepreciation | 21.08K | 20.30K | 17.71K | 26.15K |
| EBITDA | -12.65M | -9.88M | -14.61M | -10.19M |
| EBIT | -12.68M | -9.90M | -14.63M | -10.22M |
| NetInterestIncome | 1.67M | 1.83M | 809.67K | 143.63K |
| InterestIncome | 1.67M | 1.83M | 809.67K | 143.63K |
| NormalizedIncome | -11.05M | -8.57M | -14.07M | -10.13M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -11.05M | -8.57M | -14.07M | -10.13M |
| TotalExpenses | 12.68M | 10.90M | 14.63M | 14.25M |
| TotalOperatingIncomeAsReported | -12.68M | -9.90M | -14.63M | -10.22M |
| DilutedAverageShares | 49.05M | 49.05M | 49.05M | 48.60M |
| BasicAverageShares | 49.05M | 49.05M | 49.05M | 48.60M |
| DilutedEPS | -0.23 | -0.17 | -0.29 | -0.21 |
| BasicEPS | -0.23 | -0.17 | -0.29 | -0.21 |
| DilutedNIAvailtoComStockholders | -11.05M | -8.57M | -14.07M | -10.13M |
| NetIncomeCommonStockholders | -11.05M | -8.57M | -14.07M | -10.13M |
| NetIncome | -11.05M | -8.57M | -14.07M | -10.13M |
| NetIncomeIncludingNoncontrollingInterests | -11.05M | -8.57M | -14.07M | -10.13M |
| NetIncomeContinuousOperations | -11.05M | -8.57M | -14.07M | -10.13M |
| TaxProvision | 5.54K | 3.05K | 2.82K | 2.57K |
| PretaxIncome | -11.04M | -8.57M | -14.07M | -10.13M |
| OtherIncomeExpense | -39.48K | -502.87K | -247.28K | -59.50K |
| OtherNonOperatingIncomeExpenses | -39.48K | -502.87K | -247.28K | -59.50K |
| NetNonOperatingInterestIncomeExpense | 1.67M | 1.83M | 809.67K | 143.63K |
| InterestIncomeNonOperating | 1.67M | 1.83M | 809.67K | 143.63K |
| OperatingIncome | -12.68M | -9.90M | -14.63M | -10.22M |
| OperatingExpense | 12.68M | 10.90M | 14.63M | 14.25M |
| ResearchAndDevelopment | 7.19M | 5.66M | 9.14M | 8.54M |
| SellingGeneralAndAdministration | 5.48M | 5.24M | 5.48M | 5.72M |
| GeneralAndAdministrativeExpense | 5.48M | 5.24M | 5.48M | 5.72M |
| OtherGandA | 5.48M | 5.24M | 5.48M | 5.72M |
| TotalRevenue | 0.00 | 1.00M | 0.00 | 4.04M |
| OperatingRevenue | 0.00 | 1.00M | 0.00 | 4.04M |
| Line Item | 2023-12-31 | |||
|---|---|---|---|---|
| TreasurySharesNumber | 0.00 | |||
| OrdinarySharesNumber | 49.05M | 49.05M | 49.05M | 49.04M |
| ShareIssued | 49.05M | 49.05M | 49.05M | 49.04M |
| TotalDebt | 193.77K | 215.93K | 157.50K | 131.97K |
| TangibleBookValue | 38.10M | 47.98M | 55.84M | 69.28M |
| InvestedCapital | 52.50M | 62.38M | 70.24M | 83.68M |
| WorkingCapital | 38.12M | 47.90M | 55.80M | 69.18M |
| NetTangibleAssets | 38.10M | 47.98M | 55.84M | 69.28M |
| CapitalLeaseObligations | 193.77K | 215.93K | 157.50K | 131.97K |
| CommonStockEquity | 52.50M | 62.38M | 70.24M | 83.68M |
| TotalCapitalization | 52.50M | 62.38M | 70.24M | 83.68M |
| TotalEquityGrossMinorityInterest | 52.50M | 62.38M | 70.24M | 83.68M |
| StockholdersEquity | 52.50M | 62.38M | 70.24M | 83.68M |
| GainsLossesNotAffectingRetainedEarnings | -135.15K | -118.09K | -115.28K | -98.88K |
| OtherEquityAdjustments | -135.15K | -118.09K | -115.28K | -98.88K |
| RetainedEarnings | -426.75M | -415.70M | -407.13M | -393.06M |
| AdditionalPaidInCapital | 479.34M | 478.15M | 477.44M | 476.79M |
| CapitalStock | 49.05K | 49.05K | 49.05K | 49.04K |
| CommonStock | 49.05K | 49.05K | 49.05K | 49.04K |
| TotalLiabilitiesNetMinorityInterest | 3.37M | 3.89M | 3.91M | 3.73M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 413.25K | 612.45K | 725.41K | 896.47K |
| OtherNonCurrentLiabilities | 211.46K | 410.66K | 523.62K | 694.67K |
| NonCurrentDeferredLiabilities | 201.79K | 201.79K | 201.79K | 201.79K |
| NonCurrentDeferredRevenue | 0.00 | |||
| NonCurrentDeferredTaxesLiabilities | 201.79K | 201.79K | 201.79K | 201.79K |
| CurrentLiabilities | 2.96M | 3.28M | 3.19M | 2.83M |
| OtherCurrentLiabilities | 126.83K | 164.38K | 184.10K | 547.27K |
| CurrentDebtAndCapitalLeaseObligation | 193.77K | 215.93K | 157.50K | 131.97K |
| CurrentCapitalLeaseObligation | 193.77K | 215.93K | 157.50K | 131.97K |
| PensionandOtherPostRetirementBenefitPlansCurrent | 785.95K | 824.39K | 920.17K | 636.48K |
| PayablesAndAccruedExpenses | 1.85M | 2.07M | 1.93M | 1.52M |
| CurrentAccruedExpenses | 750.08K | 1.07M | 1.50M | 1.11M |
| Payables | 1.10M | 1.00M | 424.65K | 402.74K |
| AccountsPayable | 1.10M | 1.00M | 424.65K | 402.74K |
| TotalAssets | 55.88M | 66.27M | 74.15M | 87.41M |
| TotalNonCurrentAssets | 14.80M | 15.10M | 15.17M | 15.40M |
| OtherNonCurrentAssets | 19.00K | 74.15K | 92.79K | 115.49K |
| GoodwillAndOtherIntangibleAssets | 14.40M | 14.40M | 14.40M | 14.40M |
| OtherIntangibleAssets | 4.80M | 4.80M | 4.80M | 4.80M |
| Goodwill | 9.60M | 9.60M | 9.60M | 9.60M |
| NetPPE | 382.41K | 621.21K | 674.76K | 881.78K |
| AccumulatedDepreciation | -402.73K | -443.51K | -432.80K | -425.20K |
| GrossPPE | 785.14K | 1.06M | 1.11M | 1.31M |
| Leases | 0.00 | 12.58K | 13.53K | 15.41K |
| OtherProperties | 356.90K | 575.41K | 629.50K | 824.22K |
| MachineryFurnitureEquipment | 428.24K | 476.73K | 464.54K | 467.36K |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 41.07M | 51.17M | 58.99M | 72.01M |
| OtherCurrentAssets | 714.54K | 174.94K | 499.40K | 577.99K |
| PrepaidAssets | 577.99K | |||
| CashCashEquivalentsAndShortTermInvestments | 40.36M | 51.00M | 58.49M | 71.43M |
| OtherShortTermInvestments | 0.00 | 39.98M | 0.00 | |
| CashAndCashEquivalents | 40.36M | 51.00M | 18.51M | 71.43M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -10.64M | -7.45M | -12.92M | -9.41M |
| IssuanceOfCapitalStock | 0.00 | 7.92K | 20.89M | |
| CapitalExpenditure | -895.00 | -21.30K | -5.01K | -28.73K |
| IncomeTaxPaidSupplementalData | 5.04K | 3.67K | 0.00 | 0.00 |
| EndCashPosition | 40.36M | 51.00M | 18.51M | 71.43M |
| BeginningCashPosition | 51.00M | 18.51M | 71.43M | 60.04M |
| EffectOfExchangeRateChanges | 3.96K | 17.27K | -16.81K | 26.55K |
| ChangesInCash | -10.64M | 32.48M | -52.91M | 11.37M |
| FinancingCashFlow | 0.00 | 7.92K | 20.78M | |
| CashFlowFromContinuingFinancingActivities | 0.00 | 7.92K | 20.78M | |
| NetOtherFinancingCharges | -118.37K | |||
| ProceedsFromStockOptionExercised | 0.00 | 6.11K | ||
| NetCommonStockIssuance | 0.00 | 7.92K | 20.89M | |
| CommonStockIssuance | 0.00 | 7.92K | 20.89M | |
| InvestingCashFlow | -697.00 | 39.91M | -40.01M | -28.73K |
| CashFlowFromContinuingInvestingActivities | -697.00 | 39.91M | -40.01M | -28.73K |
| NetInvestmentPurchaseAndSale | 0.00 | 39.93M | -40.00M | 0.00 |
| SaleOfInvestment | 0.00 | 39.93M | 19.88M | 0.00 |
| PurchaseOfInvestment | 0.00 | -59.88M | 0.00 | |
| NetPPEPurchaseAndSale | -697.00 | -21.30K | -5.01K | -28.73K |
| SaleOfPPE | 198.00 | 0.00 | ||
| PurchaseOfPPE | -895.00 | -21.30K | -5.01K | -28.73K |
| OperatingCashFlow | -10.64M | -7.43M | -12.91M | -9.38M |
| CashFlowFromContinuingOperatingActivities | -10.64M | -7.43M | -12.91M | -9.38M |
| ChangeInWorkingCapital | -979.56K | 111.99K | 334.10K | -1.21M |
| ChangeInOtherCurrentLiabilities | -176.20K | -194.88K | -145.51K | -231.74K |
| ChangeInPayablesAndAccruedExpense | -312.35K | 19.24K | 329.01K | -1.03M |
| ChangeInPayable | -312.35K | 19.24K | 329.01K | -1.03M |
| ChangeInAccountPayable | -312.35K | 19.24K | 329.01K | -1.03M |
| ChangeInPrepaidAssets | -491.00K | 287.63K | 150.60K | 50.32K |
| OtherNonCashItems | 173.52K | -151.89K | 40.72K | 216.64K |
| StockBasedCompensation | 1.19M | 710.71K | 642.52K | 1.72M |
| DepreciationAmortizationDepletion | 21.08K | 20.30K | 17.71K | 26.15K |
| DepreciationAndAmortization | 21.08K | 20.30K | 17.71K | 26.15K |
| OperatingGainsLosses | -198.00 | 449.38K | 122.47K | 286.00 |
| GainLossOnInvestmentSecurities | 448.90K | 122.47K | ||
| GainLossOnSaleOfPPE | -198.00 | 472.00 | 0.00 | 286.00 |
| NetIncomeFromContinuingOperations | -11.05M | -8.57M | -14.07M | -10.13M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for MNOV
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|